Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibefradil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H known ✓ | O95180 | 10/20 | 0.99 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 0.99 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 0.99 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.99 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.99 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.99 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.99 |
| ▸ | NPC1 | O15118 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibefradil SCHEMBL29412446 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL7400127 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL120810 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL5500513 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL18210637 | 0.99 | NPSR1 (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL2230258 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL7708100 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL29359482 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL22968530 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 | |
| Mibefradil SCHEMBL7265837 | 0.99 | CACNA1H (1.00) | MAPTMEN1KMT2ANPSR1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316085-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-12029733-B2 | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system | Tulavi Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11918595-B2 | Methods, agents, and devices for local neuromodulation of autonomic nerves | Tulavi Therapeutics, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| US-20220370345-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2022-11-24 | — | — | US | disclosed |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| US-20220280497-A1 | TREATMENT OF SEPSIS AND RELATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMIC NERVOUS SYSTEM | Tulavi Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986472-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| US-11246879-B2 | Methods, agents, and devices for local neuromodulation of autonomic nerves | Tulai Therapeutics, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2006087476-A2 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | WO | disclosed |
| EP-1680117-A2 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITY | Sanofi-Aventis (FR) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006042955-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006024777-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005046689-A2 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITY | SANOFI-AVENTIS (FR) | 2005-05-26 | — | — | WO | disclosed |
| US-20030125269-A1 | T-TYPE CALCIUM CHANNEL | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION | 2003-07-03 | — | — | US | disclosed |
| EP-1108068-A4 | T-TYPE CALCIUM CHANNEL | UNIV SOUTH ALABAMA (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2000015845-A9 | T-TYPE CALCIUM CHANNEL | UNIV SOUTH ALABAMA (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1108068-A1 | T-TYPE CALCIUM CHANNEL | South Alabama Medical Science Foundation (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000015845-A1 | T-TYPE CALCIUM CHANNEL | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125269-A1 | T-TYPE CALCIUM CHANNEL | ORAI1, IAPP, CACNA1G | CACNA1H 5/4885CACNA1G 3/4885CACNA1I 4/4885 |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, ABCB1, NCL | CACNA1H 4500/4885CACNA1G 4144/4885CACNA1I 3970/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | CACNA1H 4199/4885CACNA1G 3741/4885CACNA1I 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.